Clinical Trials Directory

Trials / Completed

CompletedNCT01219413

Influence of Aliskiren on Proteinuria

The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Medical University of Gdansk · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril in patients with non-diabetic chronic renal disease.

Detailed description

Proteinuria is a major risk factor for progression to end-stage renal disease in both diabetic and nondiabetic nephropathies. Angiotensin II and aldosterone are the key players in the development of renal failure, either directly by promoting tissue fibrosis or indirectly through their action on glomerular hemodynamic and proteinuria. Therefore, pharmacological inhibition of the renin-angiotensin-aldosterone system (RAAS) may have a beneficial impact on proteinuria and chronic kidney diseases progression. Recently, renin inhibitors, a new class of drugs that selectively inhibits angiotensin II formation at the first step of the RAAS cascade has been introduced to clinical practice. Aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of hypertension. Blood pressure (BP)-lowering effect of aliskiren is associated with a decreased generation of angiotensin I, as it blocks its generation from angiotensinogen, by inhibiting the active enzymatic site of renin. The investigators plan this study to evaluate the short-term effects of treatment with aliskiren to those of placebo and ACEI perindopril on proteinuria.

Conditions

Interventions

TypeNameDescription
DRUGAliskiren, PerindoprilRasilez 300 mg Prestarium 10 mg

Timeline

Start date
2009-03-01
Primary completion
2010-07-01
Completion
2010-09-01
First posted
2010-10-13
Last updated
2015-09-24

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT01219413. Inclusion in this directory is not an endorsement.